```

[Congressional Bills 113th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 133 Introduced in House (IH)]

113th CONGRESS
  1st Session
H. RES. 133

      Commending the progress made by anti-tuberculosis programs.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 21, 2013

 Mr. Engel (for himself, Mr. Young of Alaska, Mr. Gene Green of Texas, 
  Ms. Schakowsky, Mr. Levin, Mr. Smith of Washington, Mr. Honda, Mrs. 
 Carolyn B. Maloney of New York, Ms. Lee of California, Mr. Payne, Ms. 
Roybal-Allard, Mr. Hastings of Florida, and Ms. Lofgren) submitted the 
 following resolution; which was referred to the Committee on Foreign 
Affairs, and in addition to the Committee on Energy and Commerce, for a 
 period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                               RESOLUTION

 
      Commending the progress made by anti-tuberculosis programs.

Whereas tuberculosis (TB) is the second leading fatal global infectious disease 
        behind HIV/AIDS, claiming 3 people each minute and 1,400,000 lives each 
        year;
Whereas the global TB pandemic and the spread of drug-resistant TB present a 
        persistent public health threat to the United States, and cases of drug-
        resistant TB in the United States have increased;
Whereas TB treatment is long and arduous, ranging from 6 months to 2 years, and 
        requires multiple medications, and the side effects of treatment for 
        drug-resistant TB can include acute pain and hearing loss;
Whereas periodic TB drug shortages have occurred in many countries, including 
        the United States, because of insufficient production by manufacturers 
        and supply chain problems;
Whereas the first new drug to treat TB in the last 40 years was approved by the 
        FDA in January 2013;
Whereas diabetic patients are 3 times more likely to develop TB compared to 
        those without diabetes;
Whereas TB is the leading killer of people with HIV/AIDS in the developing 
        world, more than 1,000 people infected with HIV die every day from 
        tuberculosis, and there is also a critical need for new TB drugs that 
        can safely be taken concurrently with antiretroviral therapy for HIV;
Whereas health care workers are 2 to 3 times more likely to contract TB than the 
        general population, yet protection from infection is inadequate in many 
        countries;
Whereas TB is an under-recognized problem in children and current pediatric 
        treatments and diagnostics are inadequate;
Whereas the disease can have devastating long-term health effects including 
        deafness, blindness, and paralysis, even after cure;
Whereas TB is the third leading killer of adult women, and the stigma associated 
        with TB disproportionately affects women, often causing delays in 
        seeking care and interfering with treatment adherence;
Whereas breadwinners who become ill with TB are often too sick to work for weeks 
        or months, which can lead to financial catastrophe for their families;
Whereas the Institute of Medicine (IOM) found that the resurgence of TB in the 
        United States between 1985 and 1992 was caused by cuts in TB control 
        funding and the spread of HIV/AIDS;
Whereas the numbers of TB cases in the United States continue to decline;
Whereas drug-resistant TB that appears resistant to all medication has been 
        found in India and South Africa, and the United States has had more than 
        28 cases of Extensively Drug-Resistant TB (XDR-TB) over the last decade, 
        with 6 cases in 2011 alone;
Whereas there are indications that drugs sold over the counter in pharmacies in 
        several countries with poor national drug control systems may be fake or 
        sub-standard;
Whereas African-Americans are 8 times more likely to have TB than Caucasians, 
        and significant disparities exist among other minorities in the United 
        States, including Native Americans, Asian-Americans, and Hispanic-
        Americans;
Whereas although drugs, diagnostics, and vaccines for TB exist, many are 
        antiquated and are increasingly inadequate for controlling the global 
        epidemic;
Whereas the TB vaccine, BCG, provides some protection to children, but it has 
        little or no efficacy in adults;
Whereas progress has been made in vaccine research, with more than a dozen 
        vaccine candidates in clinical trials;
Whereas enactment of the Tom Lantos and Henry J. Hyde United States Global 
        Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization 
        Act of 2008 and the Comprehensive TB Elimination Act provided a historic 
        United States commitment to the global eradication of TB, leading to the 
        successful treatment of 4,500,000 new TB patients and 90,000 new multi-
        drug-resistant cases by 2013, while providing additional treatment 
        through coordinated multilateral efforts;
Whereas an estimated 20,000,000 people are alive today as a direct result of TB 
        programs;
Whereas a new, United States-developed diagnostic technology, called Xpert, is 
        revolutionizing the TB response;
Whereas TB-related deaths among people living with HIV in Africa have declined 
        by 28 percent since 2004;
Whereas the United States Agency for International Development (USAID) provides 
        financial and technical assistance to nearly 32 highly burdened TB 
        countries, supports the development of new diagnostic and treatment 
        tools, and is authorized to support research to develop new vaccines to 
        combat TB;
Whereas the Centers for Disease Control and Prevention (CDC), working in 
        partnership with States and territories of the United States, directs 
        the national TB elimination program and essential national TB 
        surveillance, technical assistance, and prevention activities and 
        supports the development of new diagnostic, treatment, and prevention 
        tools to combat TB;
Whereas the United States President's Emergency Plan for AIDS Relief (PEPFAR) 
        supports programs to integrate the prevention, diagnosis, and treatment 
        of TB into HIV services, as well as programs to integrate HIV 
        prevention, testing, care, and treatment into TB programs;
Whereas the National Institutes of Health, through its many institutes and 
        centers, plays the leading role in basic and clinical research into the 
        identification, treatment, and prevention of TB;
Whereas the Global Fund to Fight AIDS, Tuberculosis, and Malaria provides 90 
        percent of all international financing for TB programs worldwide and has 
        supported the detection and treatment of 9,700,000 cases of TB; and
Whereas March 24, 2013, is World Tuberculosis Day, commemorating the date in 
        1882 when Dr. Robert Koch announced his discovery of Mycobacterium 
        tuberculosis, the bacteria that causes tuberculosis: Now, therefore, be 
        it
    Resolved, That the House of Representatives--
            (1) supports the goals of World Tuberculosis Day to raise 
        awareness about tuberculosis;
            (2) commends the progress made by United States-led anti-
        tuberculosis programs; and
            (3) reaffirms its commitment to global tuberculosis control 
        made through the Tom Lantos and Henry J. Hyde United States 
        Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria 
        Reauthorization Act of 2008.
                                 <all>
```